69 related articles for article (PubMed ID: 9816213)
1. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study.
Williams RH; Stapleton AM; Yang G; Truong LD; Rogers E; Timme TL; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1996 Apr; 2(4):635-40. PubMed ID: 9816213
[TBL] [Abstract][Full Text] [Related]
2. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.
Kim IY; Ahn HJ; Zelner DJ; Shaw JW; Lang S; Kato M; Oefelein MG; Miyazono K; Nemeth JA; Kozlowski JM; Lee C
Clin Cancer Res; 1996 Aug; 2(8):1255-61. PubMed ID: 9816295
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
Masi L; Malentacchi C; Campanacci D; Franchi A
Virchows Arch; 2002 May; 440(5):491-7. PubMed ID: 12021923
[TBL] [Abstract][Full Text] [Related]
4. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis.
Guo Y; Kyprianou N
Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572
[TBL] [Abstract][Full Text] [Related]
5. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of transforming growth factor beta 1 and nm-23 H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters.
Stravodimos K; Constantinides C; Manousakas T; Pavlaki C; Pantazopoulos D; Giannopoulos A; Dimopoulos C
Anticancer Res; 2000; 20(5C):3823-8. PubMed ID: 11268461
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
8. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
Tang B; de Castro K; Barnes HE; Parks WT; Stewart L; Böttinger EP; Danielpour D; Wakefield LM
Cancer Res; 1999 Oct; 59(19):4834-42. PubMed ID: 10519393
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression of TGF-beta1, TbetaRI, and TbetaRII correlates with differentiation in human oral squamous cell carcinomas.
Mincione G; Di Marcantonio MC; Artese L; Vianale G; Piccirelli A; Piccirilli M; Perrotti V; Rubini C; Piattelli A; Muraro R
Int J Oncol; 2008 Feb; 32(2):323-31. PubMed ID: 18202754
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways.
Park JI; Lee MG; Cho K; Park BJ; Chae KS; Byun DS; Ryu BK; Park YK; Chi SG
Oncogene; 2003 Jul; 22(28):4314-32. PubMed ID: 12853969
[TBL] [Abstract][Full Text] [Related]
11. Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
Muro-Cacho CA; Anderson M; Cordero J; Muñoz-Antonia T
Clin Cancer Res; 1999 Jun; 5(6):1243-8. PubMed ID: 10389906
[TBL] [Abstract][Full Text] [Related]
12. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy.
Shariat SF; Menesses-Diaz A; Kim IY; Muramoto M; Wheeler TM; Slawin KM
Urology; 2004 Jun; 63(6):1191-7. PubMed ID: 15183988
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
14. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
15. The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability.
Jiang X; Zeng HS; Guo Y; Zhou ZB; Tang BS; Li FK
Chin Med J (Engl); 2004 Dec; 117(12):1825-9. PubMed ID: 15603712
[TBL] [Abstract][Full Text] [Related]
16. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
17. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.
Kim IY; Ahn HJ; Lang S; Oefelein MG; Oyasu R; Kozlowski JM; Lee C
Clin Cancer Res; 1998 Jul; 4(7):1625-30. PubMed ID: 9676836
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
19. Role of transforming growth factor-beta1 in prostate cancer.
Wikström P; Damber J; Bergh A
Microsc Res Tech; 2001 Feb; 52(4):411-9. PubMed ID: 11170300
[TBL] [Abstract][Full Text] [Related]
20. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Yamamoto N; Imai J; Watanabe M; Hiroi N; Sugano S; Yoshino G
Horm Metab Res; 2006 Mar; 38(3):159-66. PubMed ID: 16673206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
